Anzeige
Mehr »
Mittwoch, 31.12.2025 - Börsentäglich über 12.000 News
Diese Batterie-Revolution könnte 2026 alles schlagen - jetzt hinschauen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
115 Leser
Artikel bewerten:
(0)

New ScienceCloud Mobile Applications by Accelrys Drive Collaborative Drug Discovery

SAN DIEGO, April 17, 2014 /PRNewswire/ -- Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software and solutions, today announced the availability of two new mobile applications supporting key life sciences workflows and real-time collaboration spanning both the ScienceCloud workspace and on-premises systems. ScienceCloud is a secure, SaaS-based, mobile-enabled information management and collaboration environment that improves data and knowledge sharing for globally networked researchers. Bi-directional integration between ScienceCloud and existing on-premises systems lets life sciences organizations migrate to the cloud in a measured fashion, continuing to leverage critical legacy applications as long as needed.

Author Tasks in Pipeline Pilot and Deploy Them to Your Mobile Devices

ScienceCloud Tasks: Engage with external partners via mobile phone

ScienceCloud Projects: Access, search and share project data

"Leading life sciences companies are looking for innovative, cloud-based collaborative research solutions that can address the needs of today's scientific workforce, who increasingly rely on social networking and mobile communication for productivity gains," said Matt Hahn, Ph.D., senior vice president and chief technology officer at Accelrys. "Our new mobile ScienceCloud offering is a game-changer, providing new task-based and project-based applications for the many mobile devices that are rapidly becoming ubiquitous in laboratories today."

With ScienceCloud Tasks, scientists using the industry-standard Accelrys Pipeline Pilot scientific authoring application and the Accelrys Mobile Collection can rapidly build and test mobile-ready protocols supporting key life science tasks and deploy them to mobile users in a networked organization. As well as working in the cloud, the application also works with local, on-premises Pipeline Pilot deployments, supporting mobile workflows in server-based environments. With ScienceCloud Tasks, protocol authors can leverage mobile functions including image capture, location services, chemistry sketching and audio/video/speech handling. Project teams can produce mobile-optimized charts and graphs scaled to particular mobile devices and assign specific tasks to particular members. ScienceCloud Tasks improves workflow efficiency and productivity by enabling mobile-enabled scientists and researchers to:

  • View status reports and project dashboards
  • Run scientific workflow tasks (upload images to Notebook, scan barcodes, perform chemical searches, etc.)
  • Share task results with other mobile users

ScienceCloud Projects allows collaborative teams to communicate around research projects via mobile devices. Mobile-enabled scientists can access and search real-time project data and engage in project-related conversations, anywhere and anytime, improving collaboration and accelerating innovation by enabling project teams to:

  • View project status and communicate results
  • Access, search and share project data
  • Post and read project-related social media-like updates
  • Receive instant notifications of new shared information

ScienceCloud Tasks and ScienceCloud Projects are part of an open and growing ecosystem of web and mobile applications developed by Accelrys and third-party software partners to address the current and future informatics needs of externalized drug discovery projects. ScienceCloud Tasks was developed in collaboration with Eidogen-Sertanty, one of ScienceCloud's early partners.

ScienceCloud Tasks and ScienceCloud Projects are available now as free downloads from the Apple® App StoreSM.

To learn more about ScienceCloud mobile enablement, register for the complimentary webinar entitled "Research Collaboration Going Mobile," scheduled for Tuesday, May 6, 2014, 8:00 AM - 9:00 AM PDT.

If you are at BioIT World in Boston (April 29-May 1), you are invited to attend the presentation by Accelrys CTO Matt Hahn entitled "Accelrys ScienceCloud: A Hosted Strategy for Collaborative R&D" (Collaborations and Open Access Innovations Track 11, Wednesday, April 30 at 2:55 PM).

Apple is a registered trademark of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc., registered in the U.S. and other countries.

About Accelrys, Inc.
Accelrys (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, supports industries and organizations that rely on scientific innovation to differentiate themselves. The industry-leading Accelrys Enterprise Platform provides a broad, flexible scientific foundation optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, QA/QC and manufacturing phases of product development. Accelrys offers capabilities in scientific data management, modelling and simulation, research informatics, laboratory informatics, enterprise quality management, environmental health & safety and operations intelligence for customers in science-driven industries. Using Accelrys technology, scientific innovators can access, organize, analyse and share data in unprecedented ways across the research, laboratory and manufacturing continuum, ultimately enhancing innovation, improving productivity and compliance, reducing costs and accelerating product development from research to manufacturing.

Accelrys solutions are used by more than 2,000 customers in the pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged goods and industrial products industries. Headquartered in San Diego, CA, Accelrys employs approximately 225 full-time Ph.D. scientists. For more information about Accelrys, visit www.accelrys.com.

Follow Accelrys on Twitter
Friend Accelrys on Facebook
Accelrys' YouTube Channel
Connect with Accelrys on LinkedIn

Accelrys, Inc. Logo

Photo - http://photos.prnewswire.com/prnh/20140416/75919
Photo - http://photos.prnewswire.com/prnh/20140416/75921
Photo - http://photos.prnewswire.com/prnh/20140416/75920
Logo- http://photos.prnewswire.com/prnh/20120416/MM88629LOGO

SOURCE Accelrys, Inc.

© 2014 PR Newswire
Renditeturbo 2026 - 5 Aktien mit Potenzial
2025 neigt sich dem Ende zu, ohne klassische Jahresendrallye, aber mit einem DAX, der viele Kritiker Lügen gestraft hat. Über 21 Prozent Kursplus seit Jahresbeginn, stärker als der US-Markt. Wer hätte das noch vor Monaten erwartet?

Genau solche Entwicklungen machen den Reiz der Börse aus. Denn auch 2026 dürfte wieder alles anders kommen als gedacht. Während viele Analysten weiter steigende Kurse erwarten, rückt eine zentrale Frage in den Fokus: Wo entstehen im kommenden Jahr echte Überraschungen, und wie kann man davon profitieren?

Unser aktueller Spezialreport beleuchtet fünf Entwicklungen, mit denen kaum jemand rechnet, die aber enormes Renditepotenzial bergen. Vom Comeback der Ölwerte über unterschätzte Plattform-Aktien bis hin zur möglichen Wachablösung im KI-Sektor: Wer 2026 überdurchschnittlich abschneiden will, muss antizyklisch denken und frühzeitig Position beziehen.

Im kostenlosen Report stellen wir 5 Aktien vor, die 2026 im Zentrum solcher Wendepunkte stehen könnten. Solide bewertet, gut positioniert und mit überraschend starkem Momentum.

Jetzt kostenlos herunterladen! Bevor andere erkennen, wo die Chancen wirklich liegen!

Dieses exklusive PDF ist nur für kurze Zeit verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.